文献速递认知障碍与痴呆

AZD0530对阿尔茨海默病脑代谢下降的影响:一项随机临床试验

Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2019-01-01

这项多中心2a期随机临床试验纳入159例轻度阿尔茨海默痴呆且PET显示β-淀粉样蛋白升高的患者,比较AZD0530(100或125 mg每日)与安慰剂治疗52周的效果。AZD0530组因不良事件停药更多,胃肠道不良事件(主要为腹泻)更常见。

要点

  • AZD0530未减缓阿尔茨海默病相关脑区相对脑葡萄糖代谢率下降。
  • 认知、日常活动、临床痴呆评分等次要终点在两组间无显著差异。
  • AZD0530组胃肠道不良事件(主要为腹泻)发生率高于安慰剂组。

核心结论

  • AZD0530治疗未在阿尔茨海默病相关兴趣区显著减缓相对脑葡萄糖代谢率下降,也未显著改善次要临床或生物标志物指标。

研究设计与样本

  • 多中心2a期随机临床试验,纳入159例轻度阿尔茨海默痴呆且PET显示β-淀粉样蛋白升高的患者,随机分配至AZD0530组(79例)或安慰剂组(80例),治疗52周。

主要发现

  • 阿尔茨海默病评估量表-认知子量表、日常活动能力、临床痴呆评分、神经精神问卷及简易精神状态检查评分变化率两组均无显著差异。
  • 磁共振体积分析显示总脑体积或脑室体积无治疗效应,但海马体积和內嗅皮层厚度下降有减缓趋势。
  • AZD0530组停药人数多于安慰剂组(21 vs 11),最常见原因为不良事件。
  • 胃肠道不良事件(主要为腹泻)在AZD0530组发生于38例(48.1%),安慰剂组23例(28.8%)。

临床怎么用

  • 本试验结果不支持AZD0530用于减缓轻度阿尔茨海默痴呆患者的脑代谢下降或认知功能衰退。
  • 使用AZD0530时需关注胃肠道不良事件(尤其是腹泻)及因不良事件导致的停药风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Oligomeric amyloid-β peptide binds to cellular prion protein on the neuronal cell surface, activating intracellular fyn kinase to mediate synaptotoxicity and tauopathy. AZD0530 is an investigational kinase inhibitor specific for the Src family, including fyn, that has been repurposed for the treatment of Alzheimer disease. OBJECTIVE: To determine whether AZD0530 treatment slows the decline in cerebral metabolic rate for glucose (CMRgl) and is safe and well tolerated. DESIGN, SETTING, AND PARTICIPANTS: This multicenter phase 2a randomized clinical trial enrolled participants between December 23, 2014, and November 30, 2016. Participants (n = 159) had mild Alzheimer dementia and positron emission tomography (PET) evidence of elevated levels of amyloid-β peptide. Efficacy analyses of all primary and secondary outcomes were conducted in a modified intention-to-treat population. Final analyses were conducted from February 9, 2018, to July 25, 2018. INTERVENTIONS: AZD0530 (100 mg or 125 mg daily) vs placebo for 52 weeks. MAIN OUTCOMES AND MEASURES: Primary outcome was the reduction in relative CMRgl, as measured by 18F-fluorodeoxyglucose (18F-FDG) PET, at 52 weeks in an Alzheimer disease-associated prespecified statistical region of interest. Secondary end points included change in cognition, function, and other biomarkers. RESULTS: Among the 159 participants, 79 were randomized to receive AZD0530 and 80 to receive placebo. Of the 159 participants, 87 (54.7%) were male, with a mean (SD) age of 71.0 (7.7) years. Based on a week-2 plasma drug level (target = 180 ng/mL; 30nM free), 15 participants (19.2%) had their AZD0530 dose escalated from 100 mg to 125 mg. Mean plasma levels from weeks 13 to 52 were 220 ng/mL and 36nM free. More participants discontinued treatment with AZD0530 than with placebo (21 vs 11), most commonly because of adverse events. The most frequent adverse events were gastrointestinal disorders (primarily diarrhea), which occurred in 38 participants (48.1%) who received AZD0530 and in 23 (28.8%) who received placebo. In the primary outcome, the treatment groups did not differ in 52-week decline in relative CMRgl (mean difference: -0.006 units/y; 95% CI, -0.017 to 0.006; P = .34). The treatment groups also did not differ in the rate of change in Alzheimer's Disease Assessment Scale-Cognitive Subscale, Alzheimer's Disease Cooperative Study-Activities of Daily Living, Clinical Dementia Rating, Neuropsychiatric Inventory, or Mini-Mental State Examination scores. Secondary volumetric magnetic resonance imaging analyses revealed no treatment effect on total brain or ventricular volume but did show trends for slowing the reduction in hippocampal volume and entorhinal thickness. CONCLUSIONS AND RELEVANCE: Statistically significant effects of AZD0530 treatment were not found on relative CMRgl reduction in an Alzheimer disease-associated region of interest or on secondary clinical or biomarker measures. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02167256.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. van Dyck CH, Nygaard HB, Chen K, et al. Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial. JAMA Neurol. 2019. PMID: 31329216. doi:10.1001/jamaneurol.2019.2050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。